Shi, H., Wang, M., Li, J., Jin, S., Zhuo, M., Zhao, J., . . . Hu, X. Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. Wiley.
Chicago Style (17th ed.) CitationShi, Huiyang, et al. Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. Wiley.
MLA (9th ed.) CitationShi, Huiyang, et al. Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. Wiley.
Warning: These citations may not always be 100% accurate.